These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25565405)

  • 1. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer.
    Sakurada T; Kakiuchi S; Tajima S; Horinouchi Y; Okada N; Nishisako H; Nakamura T; Teraoka K; Kawazoe K; Yanagawa H; Nishioka Y; Minakuchi K; Ishizawa K
    Ann Pharmacother; 2015 Apr; 49(4):398-404. PubMed ID: 25565405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of Risk Factors for Side Effects and the Establishment of Supportive Therapy during Cancer Chemotherapy].
    Sakurada T
    Yakugaku Zasshi; 2018; 138(11):1363-1370. PubMed ID: 30381644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial Lung Disease after Pleurodesis for Malignant Pleural Effusion.
    Yokoe N; Katsuda E; Kosaka K; Hamanaka R; Matsubara A; Nishimura M; Tanaka H; Asai N; Takahashi A; Kawamura T; Ishiguchi T; Yamaguchi E; Kubo A
    Intern Med; 2017; 56(14):1791-1797. PubMed ID: 28717073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
    BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
    Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
    Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world.
    Kaku S; Horinouchi H; Watanabe H; Yonemori K; Okusaka T; Boku N; Yamazaki N; Kawai A; Ohe Y; Kusumoto M
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1737-1746. PubMed ID: 35129672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
    Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
    JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer.
    Iwashita K; Mizuno T; Kumazawa S; Imaizumi K; Yamada S
    Anticancer Res; 2021 Mar; 41(3):1707-1711. PubMed ID: 33788769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
    Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
    Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
    Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.
    Osawa M; Kudoh S; Sakai F; Endo M; Hamaguchi T; Ogino Y; Yoneoka M; Sakaguchi M; Nishimoto H; Gemma A
    Int J Clin Oncol; 2015 Dec; 20(6):1063-71. PubMed ID: 25967287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
    Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
    Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
    Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
    Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.